Advanced search
Publication Cover
Journal of Medical Economics Volume 17, 2014 - Issue 2
Submit an article Journal homepage
1,236
Views
11
CrossRef citations to date
0
Altmetric
Oncology: Original Articles

Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin’s lymphoma in England and Wales

Sarah DewildeSHE BrusselsBelgium
,
Beth WoodsOxford Outcomes OxfordUK
,
Jean-Gabriel CastaigneMundipharma International Limited CambridgeUKCorrespondence[email protected]
,
Christopher ParkerOxford Outcomes OxfordUK
&
William DunlopMundipharma International Limited CambridgeUK
Pages 111-124 | Accepted 02 Dec 2013, Published online: 13 Jan 2014

Citations (11)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Wenxin Ou, Tiantian Jiang & Xiaoqiong Tang. (2023) BR (bendamustine plus rituximab) versus R-CHOP for patients with indolent B-cell lymphomas: a systematic review and Meta-analysis. Journal of Chemotherapy 35:1, pages 1-10.
Read now
Crystal Watson, Arie Barlev, Jodie Worrall, Steve Duff & Rachel Beckerman. (2021) Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients. Journal of Drug Assessment 10:1, pages 18-26.
Read now
Ziyan Chen, Yue Cheng, David DeRemer & Vakaramoko Diaby. (2021) Cost-effectiveness and drug wastage of immunotherapeutic agents for hematologic malignancies: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 21:5, pages 923-941.
Read now

Articles from other publishers (8)

Adam Suleman, Suriya J. Aktar, Zharmaine Ante, Ning Liu, Kelvin K. W. Chan, Matthew C. Cheung & Anca Prica. (2023) Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario . British Journal of Haematology.
Crossref
Nathan Fowler, Guifang Chen, Stephen Lim, Stephanie Manson, Qiufei Ma & Frank Li. (2023) reatment Patterns and Health Care Costs in Commercially Insured Patients with Follicular Lymphoma. Journal of Health Economics and Outcomes Research, pages 148-157.
Crossref
Youwen Zhu, Kun Liu, Hong Zhu & Haijun Wu. (2023) Immune checkpoint inhibitors plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer: a cost-effectiveness analysis. Therapeutic Advances in Gastroenterology 16.
Crossref
Han-I Wang, Eve Roman, Simon Crouch, Eline Aas, Cathy Burton, Russell Patmore & Alexandra Smith. (2018) A Generic Model for Follicular Lymphoma: Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population–Based Observational Data. Value in Health 21:10, pages 1176-1185.
Crossref
Eliazar Sabater, Armando López-Guillermo, Antonio Rueda, Antonio Salar, Itziar Oyagüez & Juan Manuel Collar. (2016) Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain. Applied Health Economics and Health Policy 14:4, pages 465-477.
Crossref
Karen Lien, Matthew C. Cheung & Kelvin K.W. Chan. (2016) Adjusting for Drug Wastage in Economic Evaluations of New Therapies for Hematologic Malignancies: A Systematic Review. Journal of Oncology Practice 12:4, pages e369-e379.
Crossref
Qiushi Chen, Turgay Ayer, Loretta J. Nastoupil, Adam C. Rose & Christopher R. Flowers. (2015) Comparing the Cost-Effectiveness of Rituximab Maintenance and Radioimmunotherapy Consolidation versus Observation Following First-Line Therapy in Patients with Follicular Lymphoma. Value in Health 18:2, pages 189-197.
Crossref
Lidia Gil, Maciej Kazmierczak, Renata Kroll-Balcerzak & Mieczyslaw Komarnicki. (2014) Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma. Medical Oncology 31:5.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.